MedTrace Logo

Comparison of CHS-1420 Versus Humira in Subjects With Chronic Plaque Psoriasis

NCT02489227 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 545

Last updated 2020-04-08

Study results available
· View outcomes & findings →

Summary

This is a 3-period study comparing CHS-1420 to Humira in patients with chronic plaque psoriasis.

Conditions

Interventions

DRUG

CHS-1420

DRUG

Adalimumab

Sponsors & Collaborators

  • Coherus Oncology, Inc.

    lead INDUSTRY

Principal Investigators

  • Barbara P Finck, M.D. · Coherus Oncology, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-05-06
Completion
2017-03-31
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • Canada
  • Chile
  • Croatia
  • Estonia
  • Georgia
  • Israel
  • Italy
  • Latvia
  • Moldova
  • Poland
  • Russia
  • Slovakia
  • South Africa
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02489227 on ClinicalTrials.gov